Question 10 0 out of 1 points When planning care for a patient who is receiving

Question 10 0 out of 1 points when planning care for

This preview shows page 3 - 6 out of 10 pages.

Question 100 out of 1 pointsWhen planning care for a patient who is receiving filgrastim (Neupogen) for a nonmyeloid malignancy, the nurse should formulate which of the following patient outcomes? (Select all that apply.)ResponseDesired outcomes for a patient receiving filgrastim include that febrile
Background image
Feedback:neutropenia will be avoided and infection and bone pain will not develop, or at least bone pain will not be unmanageable if it develops. Also, because this drug is administered subcutaneously every day during therapy, management of their own administration would be a positive outcome for patients. A patient who is taking oprelvekin would be at risk for fluid retention. Filgrastim is not associated with this adverse effect.Question 111 out of 1 pointsA 45-year-old woman with acute leukemia is going to begin chemotherapy with vincristine. The nurse is aware that vincristine must always be administeredResponseFeedback:If vincristine is administered as a continuous infusion, a central line should always be used. It is important to prime IV lines for chemotherapy administration with 5% dextrose in water or normal saline, not with vincristine, before administering the drug. The infusion rate, although important, is not as important a factor for vincristine administration as is the need for a central line.Question 121 out of 1 pointsA patient with chronic lymphocytic leukemia (CLL) will imminently begin a course of treatment with rituximab. In order to minimize the risk of adverse effects, what strategy for administration will be adopted?ResponseFeedback:If no reactions are apparent after 30 minutes of rituximab infusion, the dose may be escalated every 30 minutes by 50 mg/h until a maximum infusion rate of 400 mg/h is reached. Admission to an ICU and administration of diphenhydramine do not reduce the risk of adverse effects. Rituximab is not administered through multiple IV sites simultaneously.Question 131 out of 1 pointsA nurse is caring for a 64-year-old female patient who is receiving IV heparin and reports bleeding from her gums. The nurse checks the patient's laboratory test results and finds that she has a very high aPTT. The nurse anticipates that which of the following drugs may be ordered?ResponseFeedback:If a patient who receives IV heparin is found to be highly anticoagulated, protamine sulfate may be prescribed. Protamine sulfate, which is a strong base, reacts with heparin, which is a strong acid, to form a stable salt, thereby neutralizing the anticoagulant effects of heparin. Protamine sulfate does not produce the same effects for coumadin, alteplase, or ticlopidine.Question 141 out of 1 points
Background image
Intravenous carmustine has been prescribed for a patient with cancer. The nurse should help relieve the discomfort of pain and burning during the infusion byResponseFeedback:The nurse can relieve the discomfort of infusion by slowing the infusion, increasing the volume used for dilution, and increasing the total volume of the primary IV infusion. Giving 2 units of bleomycin before administering carmustine would not help relieve discomfort.
Background image
Image of page 6

You've reached the end of your free preview.

Want to read all 10 pages?

  • Fall '13
  • Chemotherapy, Leukemia, Rituximab, epoetin alfa

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture